Benzofurans ; therapeutic use ; China ; Fibrinolytic Agents ; therapeutic use ; Humans ; Stroke ; drug therapy

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; drug therapy ; Female ; Fibrinolytic Agents ; therapeutic use ; Humans

Superior vena cava syndrome can occur from benign conditions that might not alter life expectancy. Here we present a case of a superior vena cava (SVC) obstruction caused by soft tissue encircling the SVC, which was strongly suspected of being an unusual focal type of fibrosing mediastinitis. A 39-year-old man with no prior medical history presented with a four-week history of facial plethora, headache and dilated veins of the neck with a dark purple color change on the anterior chest wall. Radiology examinations, including venography, and computed tomography with a 3-dimensional volume-rendering image of the chest, had revealed severe narrowing of the SVC due to tiny encircling soft tissue and collateral vessels. A total occlusion of the SVC occurred as a result of a thrombus that developed within 1 day after the diagnostic SVC angiogram. The patient underwent stent deployment three days after the administration of thrombolytic therapy.
Adult ; Fibrinolytic Agents/therapeutic use ; Humans ; Male ; *Stents ; Superior Vena Cava Syndrome/*diagnosis/etiology/surgery

Atrial Fibrillation ; complications ; drug therapy ; Coronary Artery Disease ; complications ; drug therapy ; Fibrinolytic Agents ; therapeutic use ; Humans

Cranial Sinuses ; Dilatation ; Fibrinolytic Agents/therapeutic use* ; Humans ; Sinus Thrombosis, Intracranial/therapy* ; Thrombolytic Therapy ; Treatment Outcome

Humans ; Cardiovascular Diseases/drug therapy* ; Fibrinolytic Agents/therapeutic use* ; Hemorrhage ; Anticoagulants ; Platelet Aggregation Inhibitors

Humans ; Cardiovascular Diseases/drug therapy* ; Fibrinolytic Agents/therapeutic use* ; Hemorrhage ; Anticoagulants ; Platelet Aggregation Inhibitors

Acute Coronary Syndrome ; drug therapy ; China ; Fibrinolytic Agents ; therapeutic use ; Humans ; Platelet Aggregation Inhibitors ; therapeutic use ; Risk Assessment

Fibrinolytic Agents ; therapeutic use ; Humans ; Lung Neoplasms ; complications ; Mesothelioma ; complications ; Pleural Effusion, Malignant ; drug therapy ; Streptokinase ; therapeutic use

To study the effect of batroxobin(DF-521) on atherosclerosis, we divided 50 Japanese big ear rabbits into control group and high-lipid group. After the atherosclerosis model was successfully established, the high-lipid rabbits were divided into 3 groups(placebo group, treatment group 1 and treatment group 2). Batroxobin was injected in the treatment groups, and saline was injected in placebo group and control group. Getting the aorta before, inter and after treatment, dyeing the lipid, endothelium, smooth muscle, collagen fibers of the vascular plaque(the elastic fibers are of autofluorescence), we observed them with the light microscope and laser scanning confocal microscope. From the results, we found that the atherosclerotic plaque in the treatment groups, tended to be static four weeks later, but there was no obvious difference between treatment group 1 and treatment group 2. These implied that batroxobin possessed the action of stabilizing the atherosclerotic plaque, but the dosage-effect was not clear and the principle needed more study.
Animals ; Arteriosclerosis ; drug therapy ; pathology ; Batroxobin ; therapeutic use ; Disease Models, Animal ; Female ; Fibrinolytic Agents ; therapeutic use ; Male ; Rabbits